Selenium as a risk factor for cardiovascular diseases
Tirzepatide works by: Slowing gastric emptying, which prolongs the time food remains in the stomach Reducing gastrointestinal motility Modulating gut hormone responses Reducing appetite and food intake This delayed gastric emptying is therapeutically beneficial for glycaemic control and weight management, as it promotes satiety and reduces postprandial glucose excursions
The results showed high heterogeneity of weight loss from the baseline weight between individuals even at the highest dose of tirzepatide 38.4 to 9.0 kg and mean 22.1 kg
ABSTRACT KEY FIGURE Highlights The DEVELOPMENT AND USE OF GLUCAGON-LIKE PEPTIDE-1 STRUCTURE, DISTRIBUTION, AND PHYSIOLOGICAL FUNCTION OF GLP-1 GLP-1 MODULATES LIPID METABOLISM CLINICAL APPLICATION OF GLP-1 IN LIPID METABOLISM AND ADIPOSE-RELATED DISORDERS GLP-1 AND DUAL AGONISTS CONCLUSIONS NOTES REFERENCES About this article ABSTRACT Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus
2.4 Outcomes The primary outcome was incident pulmonary embolism
In the future, the effect can be enhanced by optimizing the delivery system (such as nanocarriers, microneedle technology) or combining treatment regimens